CONTEXT: Vesicoureteral reflux (VUR) is present in approximately 1% of children in North America and Europe and is associated with an increased risk of pyelonephritis and renal scarring. Despite its prevalence and potential morbidity, however, many aspects of VUR management are controversial. OBJECTIVE: Review the evidence surrounding current controversies in VUR diagnosis, screening, and treatment. EVIDENCE ACQUISITION: A systematic review was performed of Medline, Embase, Prospero, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, clinicaltrials.gov, and the most recent guidelines of relevant medical specialty organizations. EVIDENCE SYNTHESIS: We objectively assessed and summarized the published data, focusing on recent areas of controversy relating to VUR screening, diagnosis, and treatment. CONCLUSIONS: The evidence base for many current management patterns in VUR is limited. Areas that could significantly benefit from additional future research include improved identification of children who are at risk for VUR-related renal morbidity, improved stratification tools for determining which children would benefit most from which VUR treatment option, and improved reporting of long-term outcomes of VUR treatments. Copyright Â
CONTEXT: Vesicoureteral reflux (VUR) is present in approximately 1% of children in North America and Europe and is associated with an increased risk of pyelonephritis and renal scarring. Despite its prevalence and potential morbidity, however, many aspects of VUR management are controversial. OBJECTIVE: Review the evidence surrounding current controversies in VUR diagnosis, screening, and treatment. EVIDENCE ACQUISITION: A systematic review was performed of Medline, Embase, Prospero, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, clinicaltrials.gov, and the most recent guidelines of relevant medical specialty organizations. EVIDENCE SYNTHESIS: We objectively assessed and summarized the published data, focusing on recent areas of controversy relating to VUR screening, diagnosis, and treatment. CONCLUSIONS: The evidence base for many current management patterns in VUR is limited. Areas that could significantly benefit from additional future research include improved identification of children who are at risk for VUR-related renal morbidity, improved stratification tools for determining which children would benefit most from which VUR treatment option, and improved reporting of long-term outcomes of VUR treatments. Copyright Â
Authors: Jessica C Lloyd; Talitha Yen; Ricardo Pietrobon; John S Wiener; Sherry S Ross; Paul J Kokorowski; Caleb P Nelson; Jonathan C Routh Journal: J Pediatr Urol Date: 2014-04-04 Impact factor: 1.830
Authors: Caleb P Nelson; Jonathan C Routh; Tanya Logvinenko; Ilina Rosoklija; Paul J Kokorowski; Lisa A Prosser; Mark A Schuster Journal: J Pediatr Urol Date: 2015-04-30 Impact factor: 1.830
Authors: Rohit Tejwani; Hsin-Hsiao S Wang; Jessica C Lloyd; Paul J Kokorowski; Caleb P Nelson; Jonathan C Routh Journal: J Urol Date: 2016-10-13 Impact factor: 7.450
Authors: Martin A Koyle; Hissan Butt; Armando Lorenzo; Gerald C Mingin; Jack S Elder; Grahame H H Smith Journal: Pediatr Surg Int Date: 2017-01-20 Impact factor: 1.827